Carlos Gómez-Martín

Author

Carlos Gómez-Martín

Hospital Universitario 12 De Octubre ORCID

Also Known As

C Gomez-Martin, C Gómez-Martin, C Gómez-Martín, C. Gomez-Martin, C. Gómez-Martín, Carlos Gomez-Martin, Carlos Gomez-Martín, Carlos Gomez‐Martin, Carlos Gómez Martín, Carlos Gómez-Martin

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario 12 De Octubre Research Institute Hospital 12 de Octubre Spanish National Cancer Research Centre Clinica Universidad de Navarra Hospital Universitario HM Sanchinarro

About

Carlos Gómez-Martín is an author at Hospital Universitario 12 De Octubre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.3K
2	Health Sciences	1	1	19
3	Public Health	1	1	26
4	Emergency Medicine	1	1	26
5	Epidemiology	1	1	26

Carlos Gómez-Martín

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata, Journal of Hepatology HepatologyViral HepatitisMedicineImmunologyPathology	2013	977
Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab Carlos Gómez-Martín, Carlos Plaza, Roberto Pazo-Cid, Journal of Clinical Oncology	2013	195
Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation Carlos Gómez-Martín, Javier Bustamante, J.F. Castroagudı́n, Liver Transplantation	2011	161
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death Ramón Yarza, Mateo Bover, D. Paredes, European Journal of Cancer	2020	98
HER2/ <i>neu</i> testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer Carlos Gómez-Martín, Elena Garralda, María José Echarri, Journal of Clinical Pathology	2012	91
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer Cristina Grávalos, Carlos Gómez-Martín, Fernando Rivera, Clinical & Translational Oncology Gastrointestinal OncologyMedicineGastroenterologyPhase Ii StudyPathology	2011	80
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma Richard S. Finn, Ronnie T.P. Poon, Thomas Yau, Journal of Hepatology OncologyHepatologyMedicinePathologyLiver Cancer	2013	71
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study Manuel de la Torre‐Aláez, Ana Matilla, Marı́a Varela, Journal for ImmunoTherapy of Cancer	2022	69
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab Asunción Díaz-Serrano, Bárbara Angulo, Carolina Domínguez, The Oncologist	2018	51
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method Elena García-García, Carlos Gómez-Martín, Bárbara Angulo, Histopathology	2011	44

Page 1